Reckitt_Benckiser fined for Strepsils misleading ads
Analysis based on 7 articles · First reported Jun 01, 2026 · Last updated Jun 09, 2026
The ruling against Reckitt for deceptive marketing practices could lead to a decline in consumer trust for the company's products, potentially impacting its sales and stock performance. It also signals a stronger regulatory environment in Pakistan, which might influence other companies' marketing strategies to ensure greater transparency.
The India — Competition Appellate Tribunal upheld a ruling by the Pakistan — Competition Commission of Pakistan against Reckitt Pakistan Limited, finding the company guilty of deceptive marketing for its Strepsils product. Reckitt was ordered to pay a Rs. 30 million penalty and implement corrective measures, including prominently displaying 'Non-Medicated' on its packaging and running public awareness campaigns in newspapers. The case originated from a complaint by Square Distribution and Marketing System Private Limited, which alleged that Reckitt created a misleading impression of Strepsils as a medicinal product for sore throat relief, despite its deregistration as a drug and reclassification as a food item. This decision reinforces the importance of transparency in advertising and consumer protection in Pakistan.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard